Lurasidone Hydrochloride

A thiazole derivative and atypical ANTIPSYCHOTIC AGENT that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST; SEROTONIN 5-HT2 RECEPTOR ANTAGONIST, serotonin 5-HT7 receptor antagonist, and antagonist of the adrenergic α2A and α2C receptors, as well as a partial SEROTONIN 5-HT1A RECEPTOR AGONIST. It is used in the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER.

Also Known As:

Networked: 423 relevant articles (95 outcomes, 163 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Loebel, Antony: 78 articles (01/2022 - 06/2009)
2.	Pikalov, Andrei: 44 articles (03/2022 - 09/2011)
3.	Cucchiaro, Josephine: 33 articles (01/2018 - 06/2009)
4.	Rajagopalan, Krithika: 20 articles (01/2019 - 01/2013)
5.	Citrome, Leslie: 20 articles (01/2018 - 01/2011)
6.	Mao, Yongcai: 18 articles (09/2022 - 04/2015)
7.	Hsu, Jay: 16 articles (03/2022 - 02/2013)
8.	Tocco, Michael: 15 articles (09/2022 - 01/2020)
9.	Ng-Mak, Daisy: 14 articles (09/2020 - 01/2016)
10.	Silva, Robert: 12 articles (12/2017 - 09/2011)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 11/01/2022 - "Lurasidone has proven effective both in adolescents and adults in treating the acute phase of schizophrenia and reducing the risk of relapse. " 10/01/2020 - "Findings of this post-hoc analysis based on a placebo-controlled trial in patients with schizophrenia suggest that baseline CRP level combined with measures of metabolic risk significantly moderated the improvement in cognitive performance associated with lurasidone 160 mg/day (vs. placebo) treatment. Our findings underscore the importance of maintaining a low metabolic risk profile in patients with schizophrenia." 01/01/2020 - "Considering that the efficacy results of the Japan lurasidone phase 3 trials for acute schizophrenia were inconsistent, we conducted a systematic review and a random-effect model network meta-analysis of those trials to examine whether lurasidone was beneficial for the treatment of Japanese patients with acute schizophrenia. " 08/01/2017 - "In this 6-week study, lurasidone at doses of 40 and 80 mg/day demonstrated statistically significant and clinically meaningful symptom improvement in adolescent patients with schizophrenia. " 04/01/2015 - "In a pooled analysis of short-term, placebo-controlled studies, lurasidone significantly improved depressive symptoms in patients with schizophrenia."
2.	Bipolar Disorder (Manic Depressive Psychosis) 01/01/2023 - "In patients with non-rapid cycling bipolar depression, lurasidone monotherapy significantly improved depressive symptoms relative to placebo at both the 20-60 mg/day and 80-120 mg/day doses. " 01/01/2022 - "Lurasidone monotherapy for the treatment of bipolar depression significantly improved functioning and reduced indirect costs vs. placebo at week 6. Significant improvements in functioning and productivity were sustained for 6 months for both LUR-LUR and PBO-LUR." 08/31/2021 - "Lurasidone seems to be a promising treatment option in patients with treatment-resistant rapid cycling bipolar disorder." 01/01/2020 - "These results suggest that young patients with bipolar depression with normal weight and higher levels of pre-treatment CRP may show a greater placebo-adjusted improvement in depressive symptoms and cognitive performance when treated with lurasidone. " 01/01/2021 - "Long-term treatment with lurasidone (20-120 mg/day) was well-tolerated with no new safety concerns and associated with continued improvement in depressive symptoms in this international sample of patients with bipolar depression. "
3.	Major Depressive Disorder (Major Depressive Disorders) 04/01/2017 - "Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension." 01/01/2017 - "Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension-CORRIGENDUM." 04/01/2017 - "The aim of this post-hoc analysis was to evaluate the efficacy of lurasidone in treating patients with major depressive disorder (MDD) with mixed features who present with mild and moderate-to-severe levels of anxiety. " 04/01/2017 - "The aim of this post-hoc analysis was to evaluate the efficacy of lurasidone in treating major depressive disorder (MDD) with mixed features including irritability. " 04/01/2017 - "This post-hoc analysis assessed rates of symptomatic and functional remission, as well as recovery (combination of symptomatic and functional remission), in patients treated with lurasidone for major depressive disorder (MDD) associated with subthreshold hypomanic symptoms (mixed features). "
4.	Psychotic Disorders (Schizoaffective Disorder) 11/30/2022 - "There are non-controlled studies for the use of lurasidone in first episode psychosis cannabis induced. " 01/01/2023 - "Lurasidone in first-episode psychosis with predominant depressive symptoms: a case report." 11/30/2022 - "For its particular performance and tolerability, lurasidone is becoming an important option for the treatment of first-episode psychosis in youth. " 11/30/2022 - "Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report." 01/01/2022 - "Possible Lurasidone-Associated Dose-Dependent QTc Prolongation in First-Episode Psychosis."
5.	Cognitive Dysfunction 01/01/2018 - "Taken together, lurasidone treatment appeared to protect against language disturbances associated with negative and cognitive impairment in the rat model of cranial nerve involvement, providing a basis for its use in the clinical treatment of patients with cranial nerve involvement." 01/01/2017 - "Correction: Lurasidone versus treatment as usual for cognitive impairment in eurythmic patients with bipolar I disorder: a randomized, open-label, pilot study." 01/01/2017 - "Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study." 06/01/2013 - "However, the beneficial effect of lurasidone on cognitive impairment has not been evaluated in non-human primates. " 01/01/2020 - "Seven weeks of CMS induced anhedonia and cognitive impairment, which were normalised by lurasidone. "

Related Drugs and Biologics

1.	Antipsychotic Agents (Antipsychotics)
2.	Quetiapine Fumarate (Seroquel)
3.	Olanzapine (Zyprexa)
4.	Aripiprazole (Abilify)
5.	ziprasidone (Geodon)
6.	Lithium
7.	olanzapine-fluoxetine combination (Symbyax)
8.	Risperidone (Risperdal Consta)
9.	Valproic Acid (Depakote)
10.	cariprazine

Related Therapies and Procedures

1.	Therapeutics
2.	Secondary Prevention
3.	Off-Label Use
4.	Mechanical Ventilators (Ventilator)
5.	Injections